{"id":48341,"date":"2022-09-14T01:02:11","date_gmt":"2022-09-13T23:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/anteris-technologies-announces-presentation-of-first-in-human-data-for-its-novel-tavr-product-duravr-at-the-2022-annual-tct-congress-in-boston\/"},"modified":"2022-09-14T01:02:11","modified_gmt":"2022-09-13T23:02:11","slug":"anteris-technologies-announces-presentation-of-first-in-human-data-for-its-novel-tavr-product-duravr-at-the-2022-annual-tct-congress-in-boston","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/anteris-technologies-announces-presentation-of-first-in-human-data-for-its-novel-tavr-product-duravr-at-the-2022-annual-tct-congress-in-boston\/","title":{"rendered":"Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR\u2122 at the 2022 Annual TCT Congress in Boston"},"content":{"rendered":"
\n

\nInvestor Conference Call and KOL Forum From TCT 2022 Discussing DurAVR<\/b>\u2122 <\/sup>Cli<\/b>nical Data to be Hosted on Sept 19, 2022 at 8AM ET<\/b>\n<\/p>\n

BRISBANE, Australia & EGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR), a structural heart company developing DurAVR\u2122, the world\u2019s only balloon-expandable, 3D single-piece native shaped aortic valve, announced today the presentation of clinical data from its first-in-human (FIH) trial for DurAVR\u2122 <\/sup>at the annual meeting of the Transcatheter Cardiovascular Therapeutics (TCT) medical conference to be held in Boston September 16-19, 2022.\n<\/p>\n

<\/a><\/p>\n

\nThe FIH study commenced in November 2021 and thus far, has treated 13 patients with symptomatically severe aortic stenosis (AS). The study will continue to enroll patients through 2022 and details of FIH can be found at ClinicalTrials.gov (Identifier: NCT05182307). The primary and key secondary endpoints of this trial include device feasibility assessments such as success of implantation at the anatomically accurate position, and hemodynamic performance assessments including effective orifice area (EOA), mean gradient, aortic regurgitation, paravalvular leak (PVL) and Doppler Velocity Index (DVI). Patient outcomes such as stroke, myocardial infarction, life-threatening bleeds, and all-cause mortality are to be reported at 30 days and 1-year post implantation.\n<\/p>\n

\n\u201cDurAVR\u2122 represents a transformational product, and we are excited to showcase its first clinical study at one of the most prestigious interventional cardiology congresses,\u201d commented Dr. Chris Meduri, Chief Medical officer of Anteris and a practicing interventional cardiologist at the Karolinska University Hospital, Stockholm. \u201cWe have previously demonstrated that all Anteris tissue (including the FDA approved product CardioCel\u00ae) made from our patented ADAPT\u00ae technology, have zero-DNA, zero-glutaraldehyde and are hence ultradurable in the long-term because they remain calcification- free in 10-year longitudinal follow-ups. This will allow DurAVR\u2122 <\/sup>to be a true lifetime treatment for patients with AS. The FIH data produced to date now demonstrate the immediate hemodynamic benefits of Anteris\u2019 3D single-piece native shaped aortic valve delivering a larger EOA, excellent laminar flow, and improved exercise capacity. By combining immediate and long-term benefits, DurAVR\u2122 <\/sup>is perfectly suited for today\u2019s younger, more active patients,\u201d commented Wayne Paterson, Chief Executive Officer of Anteris Technologies.\n<\/p>\n

\nAnteris events at the TCT 2022 conference include:<\/b>\n<\/p>\n

\n1. DurAVR\u2122 – Design Concept and FIH Results<\/b>\n<\/p>\n